PTO/SB/08a (12-08)
formation Disclosure Statement (IDS) Filed

U.S. Patent and Trademark Office, U.S. DEPARTMENT, COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Doc code: IDS Doc description: Information Disclosure Statement (IDS) Filed

	Application Number		10658873	
	Filing Date		2003-09-05	
INFORMATION DISCLOSURE	First Named Inventor Micha		hael S. Kopreski	
STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)	Art Unit		1634	
(NOTION Submission under 57 OFK 1.33)	Examiner Name	Lu, Fr	rank Wei Min	
	Attorney Docket Numb	er	00-1312-K	

	U.S.PATENTS Remove										
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue D	)ate	Name of Pate of cited Docu	entee or Applicant ment	Releva		Lines where	
	1										
If you wis	h to ac	dd additional U.S. Pater	t citatio	n inform	ation pl	ease click the	Add button.		Add		
			U.S.P	ATENT	APPLI	CATION PUBL	LICATIONS		Remove	]	
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	1 Date   Name of Palentee or Applicant		Releva		Lines where, ges or Relev			
	1										
If you wis	If you wish to add additional U.S. Published Application citation information please click the Add button. Add										
				FOREIG	ON PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>		Kind Code4	Publication Date	Name of Patente Applicant of cited Document	e or V	vhere Re	or Relevant	T5
	1										
If you wis	h to a	dd additional Foreign Pa	atent Do	cument	citation	information pl	ease click the Add	button	Add		-
			NON	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove		
Examiner   Cite   Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.							T5				

(Not for submission under 37 CFR 1.99)

Application Number		10658873		
Filing Date		2003-09-05		
First Named Inventor Micha		uel S. Kopreski		
Art Unit		1634		
Examiner Name Lu, Fr		ank Wei Min		
Attorney Docket Number		00-1312-K		

/F.L./	1	Rajagopal et al. (1995), Int. J. Cancer 62: 661-667.	
	2	Dahiya et al. (1996), Urology 48: 963-970.	
	3	LeRiche et al. (1996), J. Clin. Endocrinol. Metab. 81: 656-662.	
	4	Pfeiffer et al. (1997), Int. J. Cancer 72: 581-586.	
	5	De Luca et al. (2000), Clin. Cancer Res. 6: 1439-1444.	
	6	Schlegel et al. (1994), Int. J. Cancer 56: 72-77.	
	7	Worm et al. (1999), Hum. Pathol. 30: 222-227.	
	8	Pawlowski et al. (2000), Cancer Detect. Prev. 24: 212-223.	
	9	Walch et al. (2001), Lab. Invest. 81: 791-801.	
	10	Sarkar et al. (1993), Diagn. Mol. Pathol. 2: 210-218.	
	11	Gebhardt et al. (1998), Biochem. Biophys. Res. Comm. 247: 319-323.	

(Not for submission under 37 CFR 1.99)

Application Number		10658873
iling Date		2003-09-05
First Named Inventor	Micha	nel S. Kopreski
Art Unit		1634
xaminer Name Lu, Fr		rank Wei Min
Attorney Docket Number		00-1312-K

/F.L./	12	Revillion et al. (1997), Clin. Chem. 43: 2114-2120.	
	13	Schneeberger et al. (1996), Anticancer Res. 16: 849-852.	
	14	Kraehn et al. (2001), Br. J. Cancer 84: 72-79.	
	15	Gamberi et al. (1998), Oncology 55: 556-563.	
	16	Sagawa et al. (2001), Cancer Letters 168: 45-50.	
	17	Christoph et al. (1999). Int. J. Cancer 84: 169-173.	
	18	Latil et al. (2000), Int. J. Cancer 89: 172-176.	
	19	Zhou et al. (1996), J. Biol. Chem. 271: 10760-10766.	
	20	Kozu et al. (1995), Genomics 25: 365-371.	
	21	Gocke et al. (2001), Clin. Chem. 47: 369, abstract 51.	
	22	Poon et al. (2001), Clin. Chem. 47: 363, abstract 11.	

( Not for submission under 37 CFR 1.99)

Application Number		10658873		
Filing Date		2003-09-05		
First Named Inventor Micha		el S. Kopreski		
Art Unit		1634		
Examiner Name	Lu, Fr	ank Wei Min		
Attorney Docket Number		00-1312-K		

23	Umovitz et al. (1999), Clin. Diag. Lab. Immunology 6: 330-335.	
24	Zhao et al. (1994), Circulation 90: 677-685.	
25	Dhillon et al. (2001), Exp. Neurol. 170: 140-148.	
26	Fleischhacker et al. (2001), Clin. Chem. 47: 369 (Oral Presentation).	X
27	El-Hefnawy et al. (2004), Clin. Chem. 50(3): 564-573.	
28	Tschentscher et al. (2000), Int. J. Clin. Lab. Res. 30(1): 13-15.	
29	Missov et al. (1999), Clinica Chimica Acta 284: 175-185.	
30	Sarko et al. (2002), J. Emerg. Med. 23(1): 57-65.	
31	Jurlander et al. (2000), Eur. Heart J. 21: 382-289.	
32	Rainer et al. (2003), Clin. Chem. 50(1): 206-208.	
33	Townsend et al. (1995), J. Mol. Cell. Cardiol. 27: 2223-2236.	
	24 25 26 27 28 29 30 31	24 Zhao et al. (1994), Circulation 90: 677-685.  25 Dhillon et al. (2001), Exp. Neurol. 170: 140-148.  26 Fleischhacker et al. (2001), Clin. Chem. 47: 369 (Oral Presentation).  27 El-Hefnawy et al. (2004), Clin. Chem. 50(3): 564-573.  28 Tschentscher et al. (2000), Int. J. Clin. Lab. Res. 30(1): 13-15.  29 Missov et al. (1999), Clinica Chimica Acta 284: 175-185.  30 Sarko et al. (2002), J. Emerg. Med. 23(1): 57-65.  31 Jurlander et al. (2000), Eur. Heart J. 21: 382-289.  32 Rainer et al. (2003), Clin. Chem. 50(1): 206-208.

STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)

Application Number		10658873		
Filing Date		2003-09-05		
First Named Inventor	Micha	uel S. Kopreski		
Art Unit		1634		
Examiner Name	Lu, Fr	ank Wei Min		
Attorney Docket Number		00-1312-K		

/F.L./	34	Mizuno et al. (2001), Blood 97(5): 1172-1179.	
/F.L./	35	Meiki et al. (1998), Leukemia 12: 311-316.	
***************************************	-36	Lee et al. (1906), Proc. Natl. Acad. Sci. U. S. A. 93: 19365-19370.	-
/F.L./	37	Eads et al. (1999), Cancer Res. 59: 2302-2306.	
	38	Robertson et al. (1999), Nucleic Acids Res. 27(11): 2291-2298.	
	39	Fleischhacker and Schmidt (2007), Biochim. Biophys. Acta 1775: 181-232.	
	40	Lion et al. (1995), Leukemia 9: 1353-1360.	
	41	El-Deiry, et al. (1991), Proc. Natl. Acad. Sci. U. S. A. 88: 3470-3474.	
	42	Lo et al. (1999), Clin. Chem. 45(8): 1292-1294.	
	43	Chen et al. (1999), Int. J. Cancer 83: 10-14.	
$\downarrow$	44	Saito et al. (2001), Hepatology 33: 561-568.	

### INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10658873		
Filing Date		2003-09-05		
First Named Inventor	Micha	nel S. Kopreski		
Art Unit		1634		
Examiner Name	Lu, Fr	ank Wei Min		
Attorney Docket Number		00-1312-K		

/F.L./			Wong et al., An Optimised protocol for the extraction of non-viral mRNA from human plasma frozen for three years," J. Clin. Pathol 57:766-768 (2004).			
			eui-st-al,,"Stability of Endegeneue and Added-RNA-in-Bleed-Specimene, Serum and Piaema," Clin. Chem. 48(10) 647-53 (2002).			
	Zhou et al., "Circulating RNA as a novel tumor marker: An in vitro study of the origins and characteristics of					
		extra	cellular RNA," Cancer Letter 259:50-60 (2008).			
If you wish to add additional non-patent literature document citation information please click the Add button Add						
EXAMINER SIGNATURE						
Examiner Signature			/Frank Lu/	Date Considered	12/22/2009	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						

1 See Kind Codes of USPTO Patent Documents at <a href="https://www.USPTO.GOV">www.USPTO.GOV</a> or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.